A Unique Cardioprotective Agent for Myocardial Ischemia

Heart Disease

Volumn 1, Issue 4, 1999, Pages 255-260

  Nawarskas, James J ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; DRUG DERIVATIVE; RIBONUCLEOSIDE;

ARTICLE; HUMAN; REPERFUSION INJURY;

AMINOIMIDAZOLE CARBOXAMIDE; HUMAN; MYOCARDIAL REPERFUSION INJURY; RIBONUCLEOSIDES;

EID: 0346491851     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Kloner RA, DeBoer LWV, Darsee JR, Ingwall JS, Braunwald E. Recovery from prolonged abnormalities of canine myocardium salvaged from ischemic necrosis by coronary reperfusion. Proc Natl Acad Sci U S A 1981;78:7152-7156.
2. Sabina RL, Kernstine KH, Boyd RL, Holmes EW, Swain JL. Metabolism of 5 amino-4-imidazolecarboxamide riboside in cardiac and skeletal muscle: effects on purine nucleotide synthesis. J Biol Chem 1982;257:10178-10183.
3. Swain JL, Sabina RL, McHale PA, Greenfield JC Jr, Holmes EW. Prolonged myocardial nucleotide depletion after brief ischemia in the open-chest dog. Am J Physiol 1982;242:H818-H826.
4. Swain JL, Hines JJ, Sabina RL, Holmes EW. Accelerated repletion of ATP and GTP pools in postischemic canine myocardium using a precursor of purine de novo synthesis. Circ Res 1982;51:102-105.
5. Glower DD, Spratt JA, Newton JR, Wolfe JA, Rankin JS, Swain JL. Dissociation between early recovery of regional function and purine nucleotide content in postischaemic myocardium in the conscious dog. Cardiovasc Res 1987;21:328-336.
6. Foker JE, Einzig S, Wang T. Adenosine metabolism and myocardial preservation. Consequences of adenosine catabolism on myocardial high-energy compounds and tissue blood flow. J Thorac Cardiovasc Surg 1980;80:506-516.
7. Isselhard W, Eitenmüller J, Mäurer W, DeVreese A, Reineke H, Czerniak A, et al. Increase in myocardial adenine nucleotides induced by adenosine: dosage, mode of application and duration, species differences. J Mol Cell Cardiol 1980; 12:619-634.
8. Babbitt DG, Virmani R, Forman MB. Intracoronary adenosine administered after reperfusion limits vascular injury after prolonged ischemia in the canine model. Circulation 1989;80:1388-1399.
9. Galiñanes M, Hearse DJ. Exogenous adenosine accelerates recovery of cardiac function and improves coronary flow after long-term hypothermic storage and transplantation. J Thorac Cardiovasc Surg 1992;104:151-158.
10. Olafsson R, Forman MB, Puett DW, Pou A, Cates CU, Friesinger GC, Virmani R. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation 1987;76:1135-1145.
11. Thomas JX Jr, Jones CE. Effect of inosine on contractile force and high-energy phosphates in ischemic hearts. Proc Soc Exp Biol Med 1979;161:468-472.
12. Devous MD Sr, Lewandowski ED. Inosine preserves ATP during ischemia and enhances recovery during reperfusion. Am J Physiol 1987;253:H1224-H1233.
13. Goldhaber SZ, Pohost GM, Kloner RA, Andrews E, Newell JB, Ingwall JS. Inosine: a protective agent in an organ culture model of myocardial ischemia. Circ Res 1982;51:181-188.
14. Dixon R, Fujitaki I, Sandoval T, Kisicki J. Acadesine (AICA-riboside): disposition and metabolism of an adenosine-regulating agent. J Clin Pharmacol 1993; 33:955-958.
15. Mubagwa K, Mullane K, Flameng W. Role of adenosine in the heart and circulation. Cardiovasc Res 1996;32:797-813.
16. Cook MA, Karmazyn M. Cardioprotective actions of adenosine and adenosine analogs. EXS 1996;76:325-344.
17. Mullane K, Bullough D. Harnessing an endogenous cardioprotective mechanism: cellular sources and sites of action of adenosine. J Mol Cell Cardiol 1995; 27:1041-1054.
18. Mullane K. Acadesine: the prototype adenosine regulating agent for reducing myocardial ischaemic injury. Cardiovasc Res 1993;27:43-47.
19. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986;236: 193-200.
20. Granato JE, Watson DD, Belardinelli L, Cannon JM, Beller GA. Effects of dipyridamole and aminophylline on hemodynamics, regional myocardial blood flow and thallium-201 washout in the setting of a critical coronary stenosis. J Am Coll Cardiol 1990;16:1760-1770.
21. Gruber HE, Hoffer ME, McAllister DR, Laikind PK, Lane TA, Schmid-Schoenbein GW, Engler RL. Increased adenosine concentration in blood from ischemic myocardium by AICA riboside: effects on flow, granulocytes, and injury. Circulation 1989;80:1400-1411.
22. Shryock JC, Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am J Cardiol 1997; 79(suppl):2-10.
23. Grisham MB, Hernandez LA, Granger DN. Adenosine inhibits ischemia reperfusion-induced leukocyte adherence and extravasation. Am J Physiol 1989;257: H1334-H1339.
24. Roberts PA, Newby AC, Hallett MR, Campbell AK. Inhibition by adenosine of reactive oxygen metabolite production by human polymorphonuclear leucocytes. Biochem J 1985;227:669-674.
25. Forman MB, Velasco CE, Jackson EK. Adenosine attenuates reperfusion injury following regional myocardial ischaemia. Cardiovasc Res 1993;27:9-17.
26. Granger CB. Adenosine for myocardial protection in acute myocardial infarction. Am J Cardiol 1997;79(suppl):44-48.
27. Kloner RA. Does reperfusion injury exist in humans? J Am Coll Cardiol 1993; 21:537-545.
28. Galiñanes M, Bullough D, Mullane KM, Hearse DJ. Sustained protection by acadesine against ischemia-and reperfusion-induced injury: studies in the transplanted rat heart. Circulation 1992;86:589-597.
29. Hori M, Kitakaze M, Takashima S, Morioka T, Sato H, Minamino T, et al. AICA riboside improves myocardial ischemia in coronary microembolization in dogs. Am J Physiol 1994;267:H1483-H1495.
30. Mauser M, Hoffmeister HM, Nienaber C, Schaper W. Influence of ribose, adenosine, and AICAR on the rate of myocardial adenosine triphosphate synthesis during reperfusion after coronary artery occlusion in the dog. Circ Res 1985;56:220-230.
31. Galiñanes M, Mullane KM, Bullough D, Hearse DJ. Acadesine and myocardial protection: studies of time of administration and dose-response relations in the rat. Circulation 1992;86:598-608.
32. Mitsos SE, Jolly SR, Lucchesi BR. Protective effects of AICA-riboside in the globally ischemic isolated cat heart. Pharmacology 1985;31:121-131.
33. Mentzer RM Jr., Ely SW, Lasley RD, Berne RM. The acute effects of AICAR on purine nucleotide metabolism and postischemic cardiac function. J Thorac Cardiovasc Surg 1988;95:286-293.
34. Ambrosio G, Jacobus WE, Mitchell MC, Litt MR, Becker LC. Effects of ATP precursors on ATP and free ADP content and functional recovery of postischemic hearts. Am J Physiol 1989;256:H560-H566.
35. Bullough DA, Potter S, Fox MH, Zhang C, Metzner EK, Mullane KM. Acadesine prevents oxidant-induced damage in the isolated guinea pig heart. J Pharmacol Exp Ther 1993;266:666-672.
36. Bullough DA, Fox MH, Mullane KM. Acadesine regulates adenosine to improve post-ischemic function in the isolated heart (abstract). J Mol Cell Cardiol 1992;24(suppl III):S6.
37. Dixon R, Gourzis J, McDermott D, Fujitaki J, Dewland P, Gruber H. AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. J Clin Pharmacol 1991;31:342-347.
38. Young MA, Mullane KM. Progressive cardiac dysfunction with repeated pacing-induced ischemia: protection by AICA-riboside. Am J Physiol 1991;261: H1570-H1577.
39. Bullough D, Fox M, Young M, Gruber H, Mullane K. Functional improvement with AICA riboside in the post ischemic guinea pig heart (abstract). Jpn J Pharmacol 1990;52(suppl II):85P.
40. Gruver EJ, Toupin D, Smith TW, Marsh JD. Acadesine improves tolerance to ischemic injury in rat cardiac myocytes. J Mol Cell Cardiol 1994;26:1187-1195.
41. Melton SM, Moomey CB Jr, Ragsdale DN, Trenthem LL, Croce MA, Fabian TC, Proctor KG. Acadesine during fluid resuscitation from shock and abdominal sepsis. Crit Care Med 1999;27:565-575.
42. Vinten-Johansen J, Nakanishi K, Zhao ZQ, McGee DS, Tan P. Acadesine improves surgical myocardial protection with blood cardioplegia in ischemically injured canine hearts. Circulation 1993;88(2):350-358.
43. Bolling SF, Groh MA, Mattson AM, Grinage RA, Gallagher KP. Acadesine (AICA-riboside) improves postischemic cardiac recovery. Ann Thorac Surg 1992;54:93-98.
44. McAllister D, Engler R, Laikind P, Finley K, Gruber H. Experimental infarct size reduction by a new mechanism: augmented adenosine release. Clin Res 1987;35:303A.
45. Zhao ZQ, Williams MW, Sato H, Hudspeth DA, McGee DS, Vinten-Johansen J, Van Wylen DGL. Acadesine reduces myocardial infarct size by an adenosine mediated mechanism. Cardiovasc Res 1995;29:495-505.
46. Tsuchida A, Yang XM, Burckhartt B, Mullane KM, Cohen MV, Downey JM. Acadesine extends the window of protection afforded by ischaemic preconditioning. Cardiovasc Res 1994;28:379-383.
47. Tsuchida A, Liu GS, Mullane K, Downey JM. Acadesine lowers temporal threshold for the myocardial infarct size limiting effect of preconditioning. Cardiovasc Res 1993;27:116-120.
48. Burckhartt B, Yang XM, Tsuchida A, Mullane KM, Downey JM, Cohen MV. Acadesine extends the window of protection afforded by ischaemic preconditioning in conscious rabbits. Cardiovasc Res 1995;29:653-657.
49. Leung JM, Stanley T III, Mathew J, Curling P, Barash P, Salmenpera M, et al. An initial multicenter, randomized controlled trial on the safety and efficacy of acadesine in patients undergoing coronary artery bypass graft surgery. Anesth Analg 1994;78:420-434.
50. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Effects of acadesine on the incidence of myocardial infarction and adverse cardiac out comes after coronary artery bypass graft surgery. Anesthesiology 1995;83:658-673.
51. Menasché P, Jamieson WRE, Flameng W, Davies MK. Acadesine: a new drug that may improve myocardial protection in coronary artery bypass grafting. J Thorac Cardiovasc Surg 1995;110:1096-1106.
52. Demeyere RH, Van Kerrebroeck CJ, Flameng WJ. Cardioprotective effects of acadesine in patients with unstable angina undergoing aortocoronary bypass surgery (abstract). Circulation 1994;90(suppl I):I-370.
53. Mangano DT. Effects of acadesine on myocardial infarction, stroke, and death following surgery: a meta-analysis of the 5 international randomized trials. JAMA 1997;277:325-332.
54. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1,000 patients. Lancet 1994;343:311-322.
55. Simes JR, Weaver DW, Ellis SG, Grines CL. Overview of the randomized trials of primary PTCA and thrombolysis in acute myocardial infarction (abstract). Circulation 1996;94(suppl I):I-331.
56. Ferguson JJ. Meeting highlights: highlights of the seventieth scientific sessions of the American Heart Association. Circulation 1998;97:1217-1220.
57. Holdright DR, Sparrow JL, Wright CL, Steiner J, Fox KM. Effect of acadesine, a new metabolic agent, on exercise-induced myocardial ischemia in chronic stable angina. Cardiovasc Drugs Ther 1994;8:193-197.
58. de Jonge R, MacLeod DC, Suryapranata H, van Es GA, Friedman J, Serruys PW, et al. Effect of acadesine on myocardial ischaemia in patients with coronary artery disease. Eur J Pharmacol 1997;337:41-44.
59. Dietrich WD, Miller LP, Prado R, Dewanjee S, Alexis N, Dewanjee MK, Gruber H. Acadesine reduces indium-labeled platelet deposition after photothrombosis of the common carotid artery in rats. Stroke 1995;26:111-116.
60. Fabian TC, Fabian MJ, Yockey JM, Proctor KG. Acadesine and lipopolysaccharide-evoked pulmonary dysfunction after resuscitation from traumatic shock. Surgery 1996;119:302-315.
61. Metabasis Therapeutics. Executive Summary: Acadesine, A Novel Therapeutic Agent for the Prevention of Cardiac Complications Associated with Surgery. San Diego, CA: Metabasis Therapeutics, 1997.
62. Metzner EK, Fox MH, Potter S, Mullane KM, Bullough DA. Acadesine (AICA riboside) attenuates reperfusion injury and oxidant-induced damage of the heart (abstract). Adv Exp Med Biol 1991:309A:347.
63. Bullough DA, Zhang C, Montag A, Mullane KM, Young MA. Adenosine-mediated inhibition of platelet aggregation by acadesine: a novel antithrombotic mechanism in vitro and in vivo. J Clin Invest 1994;94:1524-1532.
64. Mathew JP, Rinder CS, Tracey JB, Auszura LA, O'Connor T, Davis E, Smith BR. Acadesine inhibits neutrophil CD11B up-regulation in vitro and during in vivo cardiopulmonary bypass. J Thorac Cardiovasc Surg 1995;109:448-456.
65. Ishibashi Y, Quebbeman BB, Duncker DJ, Klassen C, Bache RJ. Acadesine increases blood flow in the collateralized heart during exercise. J Cardiovasc Pharmacol 1998;32:552-561.
66. Young MA, Henry C, Wong S, Bullough D, Mullane K. Acadesine reduces the frequency of coronary artery reocclusion following rt-PA induced thrombolysis in the dog. Thromb Haemost 1995;74:1348-1352.
67. Hori M, Kitakaze M, Takashima S. AICA-riboside (5-amino-4-imidazole carboxamide riboside 100), a novel adenosine potentiator, attenuates myocardial stunning (abstract). Circulation 1990;82 (suppl III):III-466.